drugset / Trial / NCT01189279

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

NCT01189279

Phase 1 Completed 42 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.

Timeline

Start
2010-10
Primary completion
2011-01
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified Topical